Clinical Trial Update: Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating vaginal prasterone for vulvar atrophy in breast cancer survivors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Genitourinary Syndrome of Menopause
• Vulvar Atrophy

Drugs mentioned

• Vaginal prasterone (prasterone)

Snippet

Sponsor: Hospital Clinic of Barcelona | Conditions: Vulvar Atrophy, Breast Cancer | Phase 4 | Status: COMPLETED